Insufficient Quality System leads to GDP Non-Compliance Report

Recommendation
9 September 2025
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
Chapter 1 of the EU GDP-Guidelines (Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use) requires a Quality System. In general, the Quality System should have written procedures e.g. in the Quality Manual and in SOPs, about how each requirement of the EU GDP-Guidelines will be implemented in the company.
Thus, wholesalers must ensure that their Quality Management Systems (QMS) is aligned with the GDP requirement. Otherwise, this can lead to a GDP Non-Compliance Report, as a recent example shows.
The competent authority of Romania (National Agency for Medicines and Medical Devices of Romania) has entered a new GPD Non-Compliance Report dated 22 January 2021 into the EudraGMDP database.
During an inspection conducted in November 2020, it came out that the company does not comply with the GDP principles on several aspects. The Romanian authority lists the following failures:
- No change control system has been implemented.
- Deviations were not documented.
- No self-inspections were performed.
- Information on staff training could not be provided.
As a consequence, the wholesale permission was suspended.
Based on the information gained during the inspection, the company only supplied medicines to Romanian customers. According to the authority, there is no need to recall the medicines distributed by this wholesaler.
Source: EudraGMDP Database (Inspection Date: 12 November 2021; Report Number: NCD/010/RO) *
* To find the respective report, please click on "Non-Compliance Reports" in the menu on the left-hand side and select in "From Date / To Date" the month the inspection took place. After clicking on "Search" the results list will be displayed, from which you can choose the report with the number mentioned above.
Related GMP News
30.06.2025EFPIA Report on Current Inspections
18.06.2025FDA Warning Letter with Supplier Qualification Observations
11.06.2025Root Cause Investigations criticised at EU Company
21.05.2025More FDA Warning Letters citing Quality Oversight
21.05.2025New Version of GMP Auditors Handbook available
21.05.2025FDA: more unannounced Inspections also outside the US